Press & News

People are different and so is their cancer, patients should be treated individually.

2cureX publishes the annual report for the fiscal year 2020

May 6, 2021

IR

Regulatory

Report

Copenhagen — May 6, 2021 — The Board of Directors and the CEO of 2cureX AB (“2cureX”) hereby publish the annual report for the fiscal year 2020. The annual report and associated audit report are available as an attached file and on the company’s website (www.2curex.com).

On May 27th, 2021 the Annual report will be presented for approval at the Annual General Meeting. Considering the risk of spreading the coronavirus and the authorities' regulations/general advice on avoiding gatherings, the Board of Directors have decided that the Annual General Meeting shall be held without a physical presence by shareholders exercising their voting rights by means of only advance voting, so-called postal voting.

To compensate for the lack of physical presence at the Annual General Meeting, 2cureX hereby invite the shareholders to participate in a live webinar on May 28th, 2021 at 10:00. Register here to participate.

For more information:

Fernando Andreu, CEO 2cureX

Mail: fa@2curex.com

Phone: +45 2279 5399
www.2curex.com

Certified Adviser

Redeye AB

Phone: +46 8 121 576 90

Mail: certifiedadviser@redeye.se

About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D microtumors that functionally resemble the patient's tumor and identifies the approved cancer treatment that most effectively kills the patient's tumor. Immediately after the test, the patient is given the selected treatment.

The first IndiTreat® product in metastatic colorectal cancer is introduced to the European market. Subsequent products help patients at different stages of colorectal cancer and other solid cancers.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com.